Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.77T
24h Vol:
$10.15B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  TERN
Terns Pharmaceuticals
TERN
62 / 100
High Growth
$6.74arrow_drop_up6.64%$0.42

Income Statement (TERN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$25.44M-$24.05M-$33.18M-$21.15M-$24.37M
EBITDA-$25.21M-$23.83M-$32.96M-$20.94M-$24.15M
gross Profit-$236.00K$1.10M-$222.00K-$217.00K-$222.00K
NET Income-$22.37M-$21.01M-$29.76M-$17.89M-$21.52M
total Revenue$0.00$1.32M$0.00$0.00$0.00

Balance Sheet (TERN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$64.67M-$79.32M-$37.12M-$80.04M-$183.31M
stockholders Equity$236.72M$255.36M$258.42M$274.15M$287.68M
total Assets$246.76M$268.51M$271.68M$289.69M$301.28M
total Debt$427.00K$603.00K$770.00K$876.00K$1.04M
total Liabilities$10.04M$13.15M$13.26M$15.54M$13.60M

Cash Flow (TERN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$0.00$13.86M$20.00K$489.00K$27.58M
free Cash Flow-$22.82M-$19.36M-$20.70M-$12.99M-$14.38M
investing Cash Flow----$90.83M$27.93M
operating Cash Flow-$22.79M-$19.31M-$20.69M-$12.99M-$14.38M

Terns Pharmaceuticals (TERN) Financials

Terns Pharmaceuticals, Inc. (TERN) is a biopharmaceutical company that focuses on developing innovative therapeutics for liver disease and cancer. The company's mission is to improve the lives of patients by transforming the treatment landscape through its novel drug candidates. TERN has a strong financial position, as evidenced by its robust income statement and balance sheet.

The income statement of Terns Pharmaceuticals, Inc. (TERN) reflects the company's financial performance over a specific period. It provides detailed information about the company's revenues, expenses, and profitability. TERN's gross profit represents the difference between its total revenue and the cost of goods sold. The net income from stockholders reflects the company's profitability after deducting expenses and taxes.

The balance sheet of Terns Pharmaceuticals, Inc. (TERN) provides a snapshot of the company's financial condition at a specific point in time. It includes information about the company's assets, liabilities, and stockholders' equity. TERN's total assets represent the company's resources, including cash equivalents and property, plant, and equipment. The total liabilities reflect the company's obligations, including its total debt.

Cash flow is a crucial aspect of Terns Pharmaceuticals, Inc. (TERN)'s financial health. The company's cash flow statement provides information about the cash generated and used by the company during a specific period. It includes operating cash flow, investing cash flow, and financing cash flow. TERN's operating cash flow represents the cash generated or used by its core business operations. The investing cash flow reflects the cash generated or used for investments, such as acquiring or disposing of assets. The financing cash flow shows the cash generated or used for activities like issuing or repurchasing stock and paying dividends.

In summary, Terns Pharmaceuticals, Inc. (TERN) is a financially strong biopharmaceutical company focused on developing innovative therapeutics. Its robust income statement and balance sheet reflect its solid financial position. The company's cash flow statement provides insights into its cash generation and utilization. TERN is committed to improving the lives of patients through its innovative drug candidates.

add Terns Pharmaceuticals to watchlist

Keep an eye on Terns Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level